GOCOVRI
Phase 2Small molecule
GOCOVRI is one of 32 small molecule programs targeting Encephalopathy. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
40 competitors in Encephalopathy
#DrugCompanyPhaseTrials
1Chronulac
SSolvay Pharmaceuticals
Approved
Golytely
BayerApproved
Zyloprim
Jazz PharmaceuticalsApproved
Glucophage
EMD SeronoApproved
Osmitrol
BB. Braun Medical Inc.
Approved
Carnitor
LLeadiant Biosciences, Inc.
Approved
Alinia
RRomark Laboratories L.C.
Phase 3
PROCRIT
WWim Janssens
Phase 3
Citicoline
UUniversity of Texas Southwestern Medical Center
Phase 3
Sildenafil ODT
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GOCOVRI. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details